Medicinova (MNOV) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Medicinova (MNOV) has outperformed Pelthos Therapeutics (PTHS) over the past year, gaining 23.6% versus a loss of 18.0%. Pelthos Therapeutics is the larger company by market cap ($78.5 million vs $74.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | PTHS |
|---|---|---|
| Share price | $1.52 | $20.50 |
| Market cap | $74.82M | $78.48M |
| 1-day change | -1.30% | 0.00% |
| YTD return | +16.03% | -33.87% |
| 1-year return | +23.58% | -18.00% |
| 5-year return | -60.21% | — |
| EPS (TTM) | $-0.21 | $-27.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $37.50 |
| 52-week low | $1.17 | $18.19 |
| Distance from 52-week high | -61.03% | -45.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +442.76% | +159.22% |
| Average volume | 327.41K | 60.55K |
| Shares outstanding | 49.22M | 3.83M |
| Employees | 6 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed PTHS by 41.6 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
MNOV vs PTHS FAQ
Which is bigger, Medicinova or Pelthos Therapeutics?
Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $78.48M compared with $74.82M for Medicinova (MNOV).
Which stock has performed better over the past year, MNOV or PTHS?
MNOV returned +23.58% over the past 12 months, compared with -18.00% for PTHS (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and Pelthos Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Medicinova and Biotechnology: Biological Products (No Diagnostic Substances) for Pelthos Therapeutics.